Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS)
In the phase II NIMBUS trial, patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) and high tumor mutational burden (TMB ≥ 9 mut/Mb) received nivolumab (3 mg/kg biweekly) and low-dose ipilimumab (1 mg/kg every 6 weeks) for 2 years or until progression...
Saved in:
| Published in | Nature communications Vol. 16; no. 1; pp. 4430 - 13 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
Nature Publishing Group UK
13.05.2025
Nature Publishing Group Nature Portfolio |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2041-1723 2041-1723 |
| DOI | 10.1038/s41467-025-59695-1 |
Cover
| Abstract | In the phase II NIMBUS trial, patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) and high tumor mutational burden (TMB ≥ 9 mut/Mb) received nivolumab (3 mg/kg biweekly) and low-dose ipilimumab (1 mg/kg every 6 weeks) for 2 years or until progression. The primary endpoint was objective response rate (ORR) per RECIST 1.1 criteria. Among 30 patients enrolled, the median TMB was 10.9 mut/Mb (range: 9–110) and the confirmed objective response rate was 20%. Secondary endpoints included progression-free survival, overall survival, clinical benefit rate, and safety and tolerability, including immune-related adverse events (irAEs). A prespecified correlative outcome was to evaluate the ORR in patients with a TMB ≥ 14 mut/Mb. Patients with TMB ≥ 14 mut/Mb (n = 6) experienced higher response rates (60% vs 12%; p = 0.041) and showed a trend towards improved progression-free survival and overall survival compared to patients with TMB < 14 mut/Mb. Exploratory genomic analyses suggested that
ESR1
and
PTEN
mutations may be associated with poor response, while clinical benefit was associated with a decrease or no change in tumor fraction by serial circulating tumor DNA during treatment. Stool microbiome analysis revealed that baseline blood TMB, PD-L1 positivity, and immune-related diarrhea are associated with distinct taxonomic profiles. In summary, some patients with hypermutated HER2-negative MBC experience extended clinical benefit with a dual immunotherapy regimen; a higher TMB, and additional genomic and microbiome biomarkers may optimize patient selection for therapy with nivolumab plus low-dose ipilimumab. (Funded by Bristol Myers Squibb; ClinicalTrials.gov identifier, NCT03789110).
The current use of immune checkpoint inhibitors without chemotherapy on patients with metastatic breast cancer (MBC) has not proven useful. Here this group reports a phase 2 NIMBUS trial evaluating the efficacy/safety of nivolumab + low dose ipilimumab in 30 patients with hypermutated HER2-negative MBC. |
|---|---|
| AbstractList | In the phase II NIMBUS trial, patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) and high tumor mutational burden (TMB ≥ 9 mut/Mb) received nivolumab (3 mg/kg biweekly) and low-dose ipilimumab (1 mg/kg every 6 weeks) for 2 years or until progression. The primary endpoint was objective response rate (ORR) per RECIST 1.1 criteria. Among 30 patients enrolled, the median TMB was 10.9 mut/Mb (range: 9–110) and the confirmed objective response rate was 20%. Secondary endpoints included progression-free survival, overall survival, clinical benefit rate, and safety and tolerability, including immune-related adverse events (irAEs). A prespecified correlative outcome was to evaluate the ORR in patients with a TMB ≥ 14 mut/Mb. Patients with TMB ≥ 14 mut/Mb (n = 6) experienced higher response rates (60% vs 12%; p = 0.041) and showed a trend towards improved progression-free survival and overall survival compared to patients with TMB < 14 mut/Mb. Exploratory genomic analyses suggested that
ESR1
and
PTEN
mutations may be associated with poor response, while clinical benefit was associated with a decrease or no change in tumor fraction by serial circulating tumor DNA during treatment. Stool microbiome analysis revealed that baseline blood TMB, PD-L1 positivity, and immune-related diarrhea are associated with distinct taxonomic profiles. In summary, some patients with hypermutated HER2-negative MBC experience extended clinical benefit with a dual immunotherapy regimen; a higher TMB, and additional genomic and microbiome biomarkers may optimize patient selection for therapy with nivolumab plus low-dose ipilimumab. (Funded by Bristol Myers Squibb; ClinicalTrials.gov identifier, NCT03789110).
The current use of immune checkpoint inhibitors without chemotherapy on patients with metastatic breast cancer (MBC) has not proven useful. Here this group reports a phase 2 NIMBUS trial evaluating the efficacy/safety of nivolumab + low dose ipilimumab in 30 patients with hypermutated HER2-negative MBC. In the phase II NIMBUS trial, patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) and high tumor mutational burden (TMB ≥ 9 mut/Mb) received nivolumab (3 mg/kg biweekly) and low-dose ipilimumab (1 mg/kg every 6 weeks) for 2 years or until progression. The primary endpoint was objective response rate (ORR) per RECIST 1.1 criteria. Among 30 patients enrolled, the median TMB was 10.9 mut/Mb (range: 9-110) and the confirmed objective response rate was 20%. Secondary endpoints included progression-free survival, overall survival, clinical benefit rate, and safety and tolerability, including immune-related adverse events (irAEs). A prespecified correlative outcome was to evaluate the ORR in patients with a TMB ≥ 14 mut/Mb. Patients with TMB ≥ 14 mut/Mb (n = 6) experienced higher response rates (60% vs 12%; p = 0.041) and showed a trend towards improved progression-free survival and overall survival compared to patients with TMB < 14 mut/Mb. Exploratory genomic analyses suggested that ESR1 and PTEN mutations may be associated with poor response, while clinical benefit was associated with a decrease or no change in tumor fraction by serial circulating tumor DNA during treatment. Stool microbiome analysis revealed that baseline blood TMB, PD-L1 positivity, and immune-related diarrhea are associated with distinct taxonomic profiles. In summary, some patients with hypermutated HER2-negative MBC experience extended clinical benefit with a dual immunotherapy regimen; a higher TMB, and additional genomic and microbiome biomarkers may optimize patient selection for therapy with nivolumab plus low-dose ipilimumab. (Funded by Bristol Myers Squibb; ClinicalTrials.gov identifier, NCT03789110). In the phase II NIMBUS trial, patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) and high tumor mutational burden (TMB ≥ 9 mut/Mb) received nivolumab (3 mg/kg biweekly) and low-dose ipilimumab (1 mg/kg every 6 weeks) for 2 years or until progression. The primary endpoint was objective response rate (ORR) per RECIST 1.1 criteria. Among 30 patients enrolled, the median TMB was 10.9 mut/Mb (range: 9–110) and the confirmed objective response rate was 20%. Secondary endpoints included progression-free survival, overall survival, clinical benefit rate, and safety and tolerability, including immune-related adverse events (irAEs). A prespecified correlative outcome was to evaluate the ORR in patients with a TMB ≥ 14 mut/Mb. Patients with TMB ≥ 14 mut/Mb (n = 6) experienced higher response rates (60% vs 12%; p = 0.041) and showed a trend towards improved progression-free survival and overall survival compared to patients with TMB < 14 mut/Mb. Exploratory genomic analyses suggested that ESR1 and PTEN mutations may be associated with poor response, while clinical benefit was associated with a decrease or no change in tumor fraction by serial circulating tumor DNA during treatment. Stool microbiome analysis revealed that baseline blood TMB, PD-L1 positivity, and immune-related diarrhea are associated with distinct taxonomic profiles. In summary, some patients with hypermutated HER2-negative MBC experience extended clinical benefit with a dual immunotherapy regimen; a higher TMB, and additional genomic and microbiome biomarkers may optimize patient selection for therapy with nivolumab plus low-dose ipilimumab. (Funded by Bristol Myers Squibb; ClinicalTrials.gov identifier, NCT03789110).The current use of immune checkpoint inhibitors without chemotherapy on patients with metastatic breast cancer (MBC) has not proven useful. Here this group reports a phase 2 NIMBUS trial evaluating the efficacy/safety of nivolumab + low dose ipilimumab in 30 patients with hypermutated HER2-negative MBC. Abstract In the phase II NIMBUS trial, patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) and high tumor mutational burden (TMB ≥ 9 mut/Mb) received nivolumab (3 mg/kg biweekly) and low-dose ipilimumab (1 mg/kg every 6 weeks) for 2 years or until progression. The primary endpoint was objective response rate (ORR) per RECIST 1.1 criteria. Among 30 patients enrolled, the median TMB was 10.9 mut/Mb (range: 9–110) and the confirmed objective response rate was 20%. Secondary endpoints included progression-free survival, overall survival, clinical benefit rate, and safety and tolerability, including immune-related adverse events (irAEs). A prespecified correlative outcome was to evaluate the ORR in patients with a TMB ≥ 14 mut/Mb. Patients with TMB ≥ 14 mut/Mb (n = 6) experienced higher response rates (60% vs 12%; p = 0.041) and showed a trend towards improved progression-free survival and overall survival compared to patients with TMB < 14 mut/Mb. Exploratory genomic analyses suggested that ESR1 and PTEN mutations may be associated with poor response, while clinical benefit was associated with a decrease or no change in tumor fraction by serial circulating tumor DNA during treatment. Stool microbiome analysis revealed that baseline blood TMB, PD-L1 positivity, and immune-related diarrhea are associated with distinct taxonomic profiles. In summary, some patients with hypermutated HER2-negative MBC experience extended clinical benefit with a dual immunotherapy regimen; a higher TMB, and additional genomic and microbiome biomarkers may optimize patient selection for therapy with nivolumab plus low-dose ipilimumab. (Funded by Bristol Myers Squibb; ClinicalTrials.gov identifier, NCT03789110). In the phase II NIMBUS trial, patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) and high tumor mutational burden (TMB ≥ 9 mut/Mb) received nivolumab (3 mg/kg biweekly) and low-dose ipilimumab (1 mg/kg every 6 weeks) for 2 years or until progression. The primary endpoint was objective response rate (ORR) per RECIST 1.1 criteria. Among 30 patients enrolled, the median TMB was 10.9 mut/Mb (range: 9-110) and the confirmed objective response rate was 20%. Secondary endpoints included progression-free survival, overall survival, clinical benefit rate, and safety and tolerability, including immune-related adverse events (irAEs). A prespecified correlative outcome was to evaluate the ORR in patients with a TMB ≥ 14 mut/Mb. Patients with TMB ≥ 14 mut/Mb (n = 6) experienced higher response rates (60% vs 12%; p = 0.041) and showed a trend towards improved progression-free survival and overall survival compared to patients with TMB < 14 mut/Mb. Exploratory genomic analyses suggested that ESR1 and PTEN mutations may be associated with poor response, while clinical benefit was associated with a decrease or no change in tumor fraction by serial circulating tumor DNA during treatment. Stool microbiome analysis revealed that baseline blood TMB, PD-L1 positivity, and immune-related diarrhea are associated with distinct taxonomic profiles. In summary, some patients with hypermutated HER2-negative MBC experience extended clinical benefit with a dual immunotherapy regimen; a higher TMB, and additional genomic and microbiome biomarkers may optimize patient selection for therapy with nivolumab plus low-dose ipilimumab. (Funded by Bristol Myers Squibb; ClinicalTrials.gov identifier, NCT03789110).In the phase II NIMBUS trial, patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) and high tumor mutational burden (TMB ≥ 9 mut/Mb) received nivolumab (3 mg/kg biweekly) and low-dose ipilimumab (1 mg/kg every 6 weeks) for 2 years or until progression. The primary endpoint was objective response rate (ORR) per RECIST 1.1 criteria. Among 30 patients enrolled, the median TMB was 10.9 mut/Mb (range: 9-110) and the confirmed objective response rate was 20%. Secondary endpoints included progression-free survival, overall survival, clinical benefit rate, and safety and tolerability, including immune-related adverse events (irAEs). A prespecified correlative outcome was to evaluate the ORR in patients with a TMB ≥ 14 mut/Mb. Patients with TMB ≥ 14 mut/Mb (n = 6) experienced higher response rates (60% vs 12%; p = 0.041) and showed a trend towards improved progression-free survival and overall survival compared to patients with TMB < 14 mut/Mb. Exploratory genomic analyses suggested that ESR1 and PTEN mutations may be associated with poor response, while clinical benefit was associated with a decrease or no change in tumor fraction by serial circulating tumor DNA during treatment. Stool microbiome analysis revealed that baseline blood TMB, PD-L1 positivity, and immune-related diarrhea are associated with distinct taxonomic profiles. In summary, some patients with hypermutated HER2-negative MBC experience extended clinical benefit with a dual immunotherapy regimen; a higher TMB, and additional genomic and microbiome biomarkers may optimize patient selection for therapy with nivolumab plus low-dose ipilimumab. (Funded by Bristol Myers Squibb; ClinicalTrials.gov identifier, NCT03789110). |
| ArticleNumber | 4430 |
| Author | Mittendorf, Elizabeth A. Lin, Nancy U. DiLullo, Molly K. Jeselsohn, Rinath Barroso-Sousa, Romualdo Li, Tianyu Basta, Ameer AlDubayan, Saud H. Reddy, Sangeetha M. Chu, Hoyin Emens, Leisha A. Silva, Carolina Alves Costa Montesion, Meagan Hughes, Melissa E. Tayob, Nabihah Kasparian, Julie Zanudo, Jorge Gomez Tejeda Overmoyer, Beth Attaya, Victoria Kuntz, Thomas M. Lange, Paulina Tolaney, Sara M. |
| Author_xml | – sequence: 1 givenname: Romualdo surname: Barroso-Sousa fullname: Barroso-Sousa, Romualdo organization: Hospital Brasília, Rede Américas – sequence: 2 givenname: Jorge Gomez Tejeda orcidid: 0000-0002-1092-0068 surname: Zanudo fullname: Zanudo, Jorge Gomez Tejeda organization: Medical Oncology, Dana-Farber Cancer Institute, Breast Oncology Program, Dana-Farber Brigham Cancer Center, Harvard Medical School – sequence: 3 givenname: Tianyu surname: Li fullname: Li, Tianyu organization: Data Science, Dana-Farber Cancer Institute – sequence: 4 givenname: Sangeetha M. orcidid: 0000-0002-8401-1481 surname: Reddy fullname: Reddy, Sangeetha M. organization: University of Texas Southwestern Medical Center – sequence: 5 givenname: Leisha A. surname: Emens fullname: Emens, Leisha A. organization: University of Pittsburgh Medical Center – sequence: 6 givenname: Thomas M. surname: Kuntz fullname: Kuntz, Thomas M. organization: Department of Biostatistics, Harvard T. H. Chan School of Public Health – sequence: 7 givenname: Carolina Alves Costa orcidid: 0000-0003-1920-142X surname: Silva fullname: Silva, Carolina Alves Costa organization: Gustave Roussy Cancer Campus (GRCC), Clinicobiome – sequence: 8 givenname: Saud H. surname: AlDubayan fullname: AlDubayan, Saud H. organization: Medical Oncology, Dana-Farber Cancer Institute – sequence: 9 givenname: Hoyin surname: Chu fullname: Chu, Hoyin organization: Medical Oncology, Dana-Farber Cancer Institute – sequence: 10 givenname: Beth orcidid: 0000-0003-4438-7000 surname: Overmoyer fullname: Overmoyer, Beth organization: Medical Oncology, Dana-Farber Cancer Institute, Breast Oncology Program, Dana-Farber Brigham Cancer Center, Harvard Medical School – sequence: 11 givenname: Paulina surname: Lange fullname: Lange, Paulina organization: Medical Oncology, Dana-Farber Cancer Institute – sequence: 12 givenname: Molly K. surname: DiLullo fullname: DiLullo, Molly K. organization: Medical Oncology, Dana-Farber Cancer Institute, Breast Oncology Program, Dana-Farber Brigham Cancer Center – sequence: 13 givenname: Meagan orcidid: 0000-0001-9155-556X surname: Montesion fullname: Montesion, Meagan organization: Foundation Medicine Inc – sequence: 14 givenname: Julie surname: Kasparian fullname: Kasparian, Julie organization: Medical Oncology, Dana-Farber Cancer Institute, Breast Oncology Program, Dana-Farber Brigham Cancer Center – sequence: 15 givenname: Melissa E. surname: Hughes fullname: Hughes, Melissa E. organization: Medical Oncology, Dana-Farber Cancer Institute, Breast Oncology Program, Dana-Farber Brigham Cancer Center – sequence: 16 givenname: Victoria surname: Attaya fullname: Attaya, Victoria organization: Medical Oncology, Dana-Farber Cancer Institute, Breast Oncology Program, Dana-Farber Brigham Cancer Center – sequence: 17 givenname: Ameer orcidid: 0000-0002-7238-6454 surname: Basta fullname: Basta, Ameer organization: Medical Oncology, Dana-Farber Cancer Institute, Breast Oncology Program, Dana-Farber Brigham Cancer Center – sequence: 18 givenname: Nancy U. orcidid: 0000-0003-2263-5413 surname: Lin fullname: Lin, Nancy U. organization: Medical Oncology, Dana-Farber Cancer Institute, Breast Oncology Program, Dana-Farber Brigham Cancer Center, Harvard Medical School – sequence: 19 givenname: Nabihah surname: Tayob fullname: Tayob, Nabihah organization: Harvard Medical School, Data Science, Dana-Farber Cancer Institute – sequence: 20 givenname: Rinath orcidid: 0000-0001-7996-7529 surname: Jeselsohn fullname: Jeselsohn, Rinath organization: Medical Oncology, Dana-Farber Cancer Institute, Breast Oncology Program, Dana-Farber Brigham Cancer Center, Harvard Medical School – sequence: 21 givenname: Elizabeth A. orcidid: 0000-0002-9762-8536 surname: Mittendorf fullname: Mittendorf, Elizabeth A. organization: Breast Oncology Program, Dana-Farber Brigham Cancer Center, Harvard Medical School, Division of Breast Surgery, Department of Surgery, Brigham and Women’s Hospital – sequence: 22 givenname: Sara M. orcidid: 0000-0002-5940-8671 surname: Tolaney fullname: Tolaney, Sara M. email: sara_tolaney@dfci.harvard.edu organization: Medical Oncology, Dana-Farber Cancer Institute, Breast Oncology Program, Dana-Farber Brigham Cancer Center, Harvard Medical School |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40360544$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kk1v1DAQhi1URNulf4ADssSlPQT8mXW4IKgKXakUCcrZGjvOrldJnNrJov57vLultBywLNnyPPN6NPMeo4M-9A6hV5S8pYSrd0lQUc4LwmQhq7KSBX2GjhgRtKBzxg8e3Q_RSUprkhevqBLiBToUhJdECnGExmu_Ce3UgcFDOyXchl9FHZLDfvCt73YB3-PV3eBiN40wuhpfXnxnRe-WMPqNw50bIeWAt9hEl6_YQm9dfI8BDyvIUosFHqOHFp9eL75--vnj7CV63kCb3Mn9OUM3ny9uzi-Lq29fFucfrworKjEWtrak5E1NWS1KJVijSmF4Q6tGmbKhDTWKg-FUSMcNV6BkY7lgjBsDFaN8hhZ72TrAWg_RdxDvdACvdw8hLjXEXHfrNDOlFMCkdNIKCnMD1Km8a1WzkjnIWh_2WsNkOldb148R2ieiTyO9X-ll2GjKyFyWueEzdHqvEMPt5NKoO5-sa1voXZiS5mw7n-2EMvrmH3QdptjnVm0pQaTKYKZePy7poZY_w80A2wM2hpSiax4QSvTWRHpvIp1NpHcm0tum8X1SynC_dPHv3__J-g3-8ciL |
| Cites_doi | 10.1056/NEJMoa1801946 10.1056/NEJMoa1809615 10.1038/s41591-021-01655-5 10.1093/jncics/pky062 10.1200/JCO.21.01015 10.1007/s10549-017-4537-5 10.1038/s43018-024-00729-w 10.1158/2326-6066.CIR-18-0291 10.1016/S1470-2045(20)30445-9 10.1158/0008-5472.CAN-23-1711 10.1158/2159-8290.CD-21-0236 10.1126/science.aan3706 10.1126/science.aad0095 10.1038/s41591-018-0134-3 10.5858/arpa.2016-0527-OA 10.1158/0008-5472.CAN-12-4100 10.1093/bioinformatics/btaa554 10.3389/fmicb.2016.01081 10.1093/annonc/mdu450 10.1016/j.cell.2014.12.033 10.1056/NEJMoa1406498 10.1136/jitc-2022-SITC2022.0029 10.1158/1538-7445.SABCS15-S5-07 10.3390/cancers15153997 10.1158/1078-0432.CCR-19-3529 10.1126/science.aaa1348 10.1016/S1470-2045(17)30422-9 10.1371/journal.pone.0237802 10.1128/JB.184.1.191-199.2002 10.1126/science.aan4236 10.1016/j.annonc.2020.08.398 10.1038/ncomms12335 10.1158/1078-0432.CCR-21-2182 10.1371/journal.pcbi.1009442 10.1371/journal.pcbi.1005965 10.18632/oncotarget.24867 10.1136/jitc-2022-SITC2022.0584 10.1126/science.aao3290 10.1073/pnas.0915174107 10.1038/s41587-023-01688-w 10.1001/jamaoncol.2020.3524 10.1016/S1470-2045(19)30689-8 10.1038/s41591-018-0238-9 10.1158/1078-0432.CCR-19-3507 10.1016/j.chom.2022.02.004 10.1038/s41698-022-00334-z 10.1200/JCO.20.02923 10.1056/NEJMoa1504030 10.1200/JCO.2021.39.15_suppl.1091 10.1007/s12609-019-00346-y 10.1200/JCO.18.01042 10.1016/S1470-2045(20)30754-3 10.1200/JCO.2017.76.9901 10.1016/j.ejca.2008.10.026 10.3390/nu12123607 10.1038/s41523-021-00328-3 10.1016/j.annonc.2019.11.010 10.1158/1538-7445.SABCS21-P2-08-08 10.1158/1538-7445.SABCS21-PD14-09 10.1093/annonc/mdy497 10.1016/S0140-6736(20)32531-9 10.6004/jnccn.2020.7543 10.1038/s41418-021-00784-1 10.1186/s40425-019-0780-0 10.1126/science.aan5931 10.1016/j.celrep.2016.10.009 10.1038/s41586-023-05940-w 10.18632/oncotarget.5950 10.7554/eLife.65088 10.1158/2159-8290.CD-21-0450 10.1056/NEJMoa1712126 10.1038/s41467-021-25769-z |
| ContentType | Journal Article |
| Copyright | The Author(s) 2025 2025. The Author(s). Copyright Nature Publishing Group 2025 The Author(s) 2025 2025 |
| Copyright_xml | – notice: The Author(s) 2025 – notice: 2025. The Author(s). – notice: Copyright Nature Publishing Group 2025 – notice: The Author(s) 2025 2025 |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7QR 7SN 7SS 7ST 7T5 7T7 7TM 7TO 7X7 7XB 88E 8AO 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA ARAPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M1P M7P P5Z P62 P64 PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS RC3 SOI 7X8 5PM DOA |
| DOI | 10.1038/s41467-025-59695-1 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Ecology Abstracts Entomology Abstracts (Full archive) Environment Abstracts Immunology Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Aerospace Collection ProQuest Central Essentials Biological Science Collection ProQuest Central ProQuest Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Medical Database Biological Science Database Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Genetics Abstracts Environment Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection Chemoreception Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Central (New) ProQuest Medical Library (Alumni) Advanced Technologies & Aerospace Collection ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Entomology Abstracts ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) AIDS and Cancer Research Abstracts ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Immunology Abstracts Environment Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Publicly Available Content Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2041-1723 |
| EndPage | 13 |
| ExternalDocumentID | oai_doaj_org_article_2b654a255e5c41a7ba1e81e8d8d262ea PMC12075640 40360544 10_1038_s41467_025_59695_1 |
| Genre | Clinical Trial, Phase II Journal Article |
| GrantInformation_xml | – fundername: The authors acknowledge receiving institutional support for this study from Bristol Myers Squibb, The Department of Defense Physician Research Award (W81XWH-21-1-0084, PC200150) and Idea Development Award—Early-Career Investigator (KC210042/W81XWH-22-1-0455) (SHA), National Comprehensive Cancer Network Oncology Research Program - Pfizer Enhancing Academic-Community-Patient Partnerships in Metastatic Breast Cancer Care. EAM acknowledges support as the Rob and Karen Hale Distinguished Chair in Surgical Oncology. |
| GroupedDBID | --- 0R~ 39C 53G 5VS 70F 7X7 88E 8AO 8FE 8FG 8FH 8FI 8FJ AAHBH AAJSJ AASML ABUWG ACGFO ACGFS ACIWK ACMJI ACPRK ADBBV ADFRT ADMLS ADRAZ AENEX AEUYN AFKRA AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AMTXH AOIJS ARAPS ASPBG AVWKF AZFZN BBNVY BCNDV BENPR BGLVJ BHPHI BPHCQ BVXVI C6C CCPQU DIK EBLON EBS EE. EMOBN F5P FEDTE FYUFA GROUPED_DOAJ HCIFZ HMCUK HVGLF HYE HZ~ KQ8 LGEZI LK8 LOTEE M1P M7P M~E NADUK NAO NXXTH O9- OK1 P2P P62 PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RNS RNT RNTTT RPM SNYQT SV3 TSG UKHRP AAYXX CITATION PJZUB PPXIY PQGLB PUEGO CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7QR 7SN 7SS 7ST 7T5 7T7 7TM 7TO 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. M48 P64 PKEHL PQEST PQUKI PRINS RC3 SOI 7X8 5PM |
| ID | FETCH-LOGICAL-c494t-cdc063fd12d46842f864b3f19f8b6f1f1b83ab3145e3b38a85fc34223bba9213 |
| IEDL.DBID | 7X7 |
| ISSN | 2041-1723 |
| IngestDate | Wed Aug 27 01:28:34 EDT 2025 Thu Aug 21 18:30:09 EDT 2025 Fri Sep 05 16:43:40 EDT 2025 Sat Aug 23 13:30:23 EDT 2025 Mon Jul 21 05:34:59 EDT 2025 Wed Sep 10 05:05:11 EDT 2025 Thu May 15 22:57:53 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | 2025. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c494t-cdc063fd12d46842f864b3f19f8b6f1f1b83ab3145e3b38a85fc34223bba9213 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0001-7996-7529 0000-0002-1092-0068 0000-0001-9155-556X 0000-0003-4438-7000 0000-0003-1920-142X 0000-0002-5940-8671 0000-0003-2263-5413 0000-0002-9762-8536 0000-0002-8401-1481 0000-0002-7238-6454 |
| OpenAccessLink | https://www.proquest.com/docview/3204058919?pq-origsite=%requestingapplication% |
| PMID | 40360544 |
| PQID | 3204058919 |
| PQPubID | 546298 |
| PageCount | 13 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_2b654a255e5c41a7ba1e81e8d8d262ea pubmedcentral_primary_oai_pubmedcentral_nih_gov_12075640 proquest_miscellaneous_3203919184 proquest_journals_3204058919 pubmed_primary_40360544 crossref_primary_10_1038_s41467_025_59695_1 springer_journals_10_1038_s41467_025_59695_1 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-05-13 |
| PublicationDateYYYYMMDD | 2025-05-13 |
| PublicationDate_xml | – month: 05 year: 2025 text: 2025-05-13 day: 13 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Nature communications |
| PublicationTitleAbbrev | Nat Commun |
| PublicationTitleAlternate | Nat Commun |
| PublicationYear | 2025 |
| Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
| References | L Derosa (59695_CR57) 2021; 11 59695_CR71 H Rugo (59695_CR6) 2016; 76 J Crowdis (59695_CR69) 2020; 36 A Blanco-Miguez (59695_CR72) 2023; 41 M Giannakis (59695_CR9) 2016; 17 L Derosa (59695_CR32) 2022; 28 J Duraiswamy (59695_CR43) 2013; 73 EM Van Allen (59695_CR12) 2015; 350 59695_CR66 ES Sokol (59695_CR38) 2019; 30 JX Sun (59695_CR65) 2018; 14 MJ Overman (59695_CR24) 2018; 36 S Sammons (59695_CR37) 2022; 82 B Routy (59695_CR29) 2018; 359 JS Bergholz (59695_CR49) 2023; 617 Y Wang (59695_CR58) 2018; 24 R Barroso-Sousa (59695_CR17) 2020; 26 HJ Lenz (59695_CR27) 2022; 40 R Woodhouse (59695_CR64) 2020; 15 EP Winer (59695_CR18) 2021; 22 JK Lee (59695_CR68) 2022; 6 MS Rooney (59695_CR8) 2015; 160 J Cortes (59695_CR4) 2020; 396 59695_CR16 RJ Motzer (59695_CR23) 2018; 378 S Chumsri (59695_CR39) 2020; 18 NA Rizvi (59695_CR11) 2015; 348 B Ricciuti (59695_CR70) 2020; 26 59695_CR56 EA Eisenhauer (59695_CR28) 2009; 45 S Chumsri (59695_CR40) 2022; 82 A Catinean (59695_CR61) 2020; 12 TE Keenan (59695_CR52) 2021; 12 P Schmid (59695_CR3) 2020; 21 SM Tolaney (59695_CR7) 2020; 6 LY Dirix (59695_CR5) 2018; 167 R Salgado (59695_CR67) 2015; 26 R Barroso-Sousa (59695_CR35) 2020; 31 MA Curran (59695_CR21) 2010; 107 LZ Shi (59695_CR45) 2016; 7 JA Trujillo (59695_CR50) 2019; 7 N Ready (59695_CR26) 2019; 37 A Marabelle (59695_CR15) 2020; 21 MJ Overman (59695_CR25) 2017; 18 EP Garcia (59695_CR62) 2017; 141 S Adams (59695_CR46) 2022; 28 F Hermida-Prado (59695_CR51) 2023; 83 H Mallick (59695_CR73) 2021; 17 CA Santa-Maria (59695_CR47) 2018; 9 JL Caswell-Jin (59695_CR1) 2018; 2 A Snyder (59695_CR10) 2014; 371 R Barroso-Sousa (59695_CR53) 2019; 11 J Cai (59695_CR55) 2022; 30 J Larkin (59695_CR22) 2015; 373 S Terrisse (59695_CR54) 2021; 28 LA Emens (59695_CR19) 2020; 31 V Matson (59695_CR31) 2018; 359 V Gopalakrishnan (59695_CR30) 2018; 359 P Schmid (59695_CR2) 2018; 379 LN Weis (59695_CR63) 2021; 7 DR Gandara (59695_CR41) 2018; 24 JD Forbes (59695_CR59) 2016; 7 LF Campesato (59695_CR14) 2015; 6 ET Roussos Torres (59695_CR48) 2024; 5 NT Hoa (59695_CR60) 2002; 184 CF Friedman (59695_CR42) 2021; 12 PA Beavis (59695_CR44) 2018; 6 59695_CR34 S Sammons (59695_CR36) 2021; 39 MD Hellmann (59695_CR13) 2018; 378 AS Alva (59695_CR20) 2021; 39 59695_CR33 |
| References_xml | – volume: 378 start-page: 2093 year: 2018 ident: 59695_CR13 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1801946 – volume: 379 start-page: 2108 year: 2018 ident: 59695_CR2 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1809615 – volume: 28 start-page: 315 year: 2022 ident: 59695_CR32 publication-title: Nat. Med. doi: 10.1038/s41591-021-01655-5 – volume: 2 year: 2018 ident: 59695_CR1 publication-title: JNCI Cancer Spectr. doi: 10.1093/jncics/pky062 – volume: 40 start-page: 161 year: 2022 ident: 59695_CR27 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.21.01015 – volume: 167 start-page: 671 year: 2018 ident: 59695_CR5 publication-title: Breast Cancer Res. Treat. doi: 10.1007/s10549-017-4537-5 – ident: 59695_CR66 – volume: 5 start-page: 866 year: 2024 ident: 59695_CR48 publication-title: Nat. Cancer doi: 10.1038/s43018-024-00729-w – volume: 6 start-page: 1069 year: 2018 ident: 59695_CR44 publication-title: Cancer Immunol. Res. doi: 10.1158/2326-6066.CIR-18-0291 – volume: 21 start-page: 1353 year: 2020 ident: 59695_CR15 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(20)30445-9 – volume: 83 start-page: 3284 year: 2023 ident: 59695_CR51 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-23-1711 – volume: 11 start-page: 2396 year: 2021 ident: 59695_CR57 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-21-0236 – volume: 359 start-page: 91 year: 2018 ident: 59695_CR29 publication-title: Science doi: 10.1126/science.aan3706 – volume: 350 start-page: 207 year: 2015 ident: 59695_CR12 publication-title: Science doi: 10.1126/science.aad0095 – volume: 24 start-page: 1441 year: 2018 ident: 59695_CR41 publication-title: Nat. Med. doi: 10.1038/s41591-018-0134-3 – volume: 141 start-page: 751 year: 2017 ident: 59695_CR62 publication-title: Arch. Pathol. Lab. Med. doi: 10.5858/arpa.2016-0527-OA – volume: 73 start-page: 3591 year: 2013 ident: 59695_CR43 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-12-4100 – volume: 36 start-page: 4348 year: 2020 ident: 59695_CR69 publication-title: Bioinformatics doi: 10.1093/bioinformatics/btaa554 – volume: 7 start-page: 1081 year: 2016 ident: 59695_CR59 publication-title: Front. Microbiol. doi: 10.3389/fmicb.2016.01081 – volume: 26 start-page: 259 year: 2015 ident: 59695_CR67 publication-title: Ann. Oncol. doi: 10.1093/annonc/mdu450 – volume: 160 start-page: 48 year: 2015 ident: 59695_CR8 publication-title: Cell doi: 10.1016/j.cell.2014.12.033 – volume: 371 start-page: 2189 year: 2014 ident: 59695_CR10 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1406498 – ident: 59695_CR33 doi: 10.1136/jitc-2022-SITC2022.0029 – volume: 76 start-page: S5-07 year: 2016 ident: 59695_CR6 publication-title: Cancer Res. doi: 10.1158/1538-7445.SABCS15-S5-07 – ident: 59695_CR16 doi: 10.3390/cancers15153997 – volume: 26 start-page: 4135 year: 2020 ident: 59695_CR70 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-19-3529 – volume: 348 start-page: 124 year: 2015 ident: 59695_CR11 publication-title: Science doi: 10.1126/science.aaa1348 – volume: 18 start-page: 1182 year: 2017 ident: 59695_CR25 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(17)30422-9 – volume: 15 start-page: e0237802 year: 2020 ident: 59695_CR64 publication-title: PLoS ONE doi: 10.1371/journal.pone.0237802 – volume: 184 start-page: 191 year: 2002 ident: 59695_CR60 publication-title: J. Bacteriol. doi: 10.1128/JB.184.1.191-199.2002 – volume: 359 start-page: 97 year: 2018 ident: 59695_CR30 publication-title: Science doi: 10.1126/science.aan4236 – volume: 31 start-page: S360 year: 2020 ident: 59695_CR19 publication-title: Ann. Oncol. doi: 10.1016/j.annonc.2020.08.398 – volume: 7 year: 2016 ident: 59695_CR45 publication-title: Nat. Commun. doi: 10.1038/ncomms12335 – volume: 28 start-page: 271 year: 2022 ident: 59695_CR46 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-21-2182 – volume: 17 start-page: e1009442 year: 2021 ident: 59695_CR73 publication-title: PLoS Comput. Biol. doi: 10.1371/journal.pcbi.1009442 – volume: 14 start-page: e1005965 year: 2018 ident: 59695_CR65 publication-title: PLoS Comput. Biol. doi: 10.1371/journal.pcbi.1005965 – volume: 9 start-page: 18985 year: 2018 ident: 59695_CR47 publication-title: Oncotarget doi: 10.18632/oncotarget.24867 – ident: 59695_CR34 doi: 10.1136/jitc-2022-SITC2022.0584 – volume: 359 start-page: 104 year: 2018 ident: 59695_CR31 publication-title: Science doi: 10.1126/science.aao3290 – volume: 107 start-page: 4275 year: 2010 ident: 59695_CR21 publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.0915174107 – volume: 41 start-page: 1633 year: 2023 ident: 59695_CR72 publication-title: Nat. Biotechnol. doi: 10.1038/s41587-023-01688-w – volume: 6 start-page: 1598 year: 2020 ident: 59695_CR7 publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2020.3524 – volume: 21 start-page: 44 year: 2020 ident: 59695_CR3 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(19)30689-8 – volume: 24 start-page: 1804 year: 2018 ident: 59695_CR58 publication-title: Nat. Med. doi: 10.1038/s41591-018-0238-9 – volume: 26 start-page: 2565 year: 2020 ident: 59695_CR17 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-19-3507 – volume: 30 start-page: 289 year: 2022 ident: 59695_CR55 publication-title: Cell Host Microbe doi: 10.1016/j.chom.2022.02.004 – volume: 6 year: 2022 ident: 59695_CR68 publication-title: NPJ Precis. Oncol. doi: 10.1038/s41698-022-00334-z – volume: 39 start-page: 2443 year: 2021 ident: 59695_CR20 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.20.02923 – volume: 373 start-page: 23 year: 2015 ident: 59695_CR22 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1504030 – volume: 39 start-page: 1091 year: 2021 ident: 59695_CR36 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2021.39.15_suppl.1091 – volume: 11 start-page: 272 year: 2019 ident: 59695_CR53 publication-title: Curr. Breast Cancer Rep. doi: 10.1007/s12609-019-00346-y – volume: 37 start-page: 992 year: 2019 ident: 59695_CR26 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.18.01042 – volume: 22 start-page: 499 year: 2021 ident: 59695_CR18 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(20)30754-3 – volume: 36 start-page: 773 year: 2018 ident: 59695_CR24 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2017.76.9901 – volume: 45 start-page: 228 year: 2009 ident: 59695_CR28 publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2008.10.026 – volume: 12 start-page: 3607 year: 2020 ident: 59695_CR61 publication-title: Nutrients doi: 10.3390/nu12123607 – volume: 7 year: 2021 ident: 59695_CR63 publication-title: NPJ Breast Cancer doi: 10.1038/s41523-021-00328-3 – volume: 31 start-page: 387 year: 2020 ident: 59695_CR35 publication-title: Ann. Oncol. doi: 10.1016/j.annonc.2019.11.010 – volume: 82 start-page: P2-08-08 year: 2022 ident: 59695_CR37 publication-title: Cancer Res. doi: 10.1158/1538-7445.SABCS21-P2-08-08 – volume: 82 start-page: PD14-09 year: 2022 ident: 59695_CR40 publication-title: Cancer Res. doi: 10.1158/1538-7445.SABCS21-PD14-09 – volume: 30 start-page: 115 year: 2019 ident: 59695_CR38 publication-title: Ann. Oncol. doi: 10.1093/annonc/mdy497 – volume: 396 start-page: 1817 year: 2020 ident: 59695_CR4 publication-title: Lancet doi: 10.1016/S0140-6736(20)32531-9 – volume: 18 start-page: 517 year: 2020 ident: 59695_CR39 publication-title: J. Natl Compr. Canc Netw. doi: 10.6004/jnccn.2020.7543 – volume: 28 start-page: 2778 year: 2021 ident: 59695_CR54 publication-title: Cell Death Differ. doi: 10.1038/s41418-021-00784-1 – volume: 7 start-page: 295 year: 2019 ident: 59695_CR50 publication-title: J. Immunother. Cancer doi: 10.1186/s40425-019-0780-0 – ident: 59695_CR56 doi: 10.1126/science.aan5931 – volume: 17 start-page: 1206 year: 2016 ident: 59695_CR9 publication-title: Cell Rep. doi: 10.1016/j.celrep.2016.10.009 – volume: 617 start-page: 139 year: 2023 ident: 59695_CR49 publication-title: Nature doi: 10.1038/s41586-023-05940-w – volume: 6 start-page: 34221 year: 2015 ident: 59695_CR14 publication-title: Oncotarget doi: 10.18632/oncotarget.5950 – ident: 59695_CR71 doi: 10.7554/eLife.65088 – volume: 12 start-page: 654 year: 2021 ident: 59695_CR42 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-21-0450 – volume: 378 start-page: 1277 year: 2018 ident: 59695_CR23 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1712126 – volume: 12 year: 2021 ident: 59695_CR52 publication-title: Nat. Commun. doi: 10.1038/s41467-021-25769-z |
| SSID | ssj0000391844 |
| Score | 2.480518 |
| Snippet | In the phase II NIMBUS trial, patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) and high tumor mutational... Abstract In the phase II NIMBUS trial, patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) and high tumor... |
| SourceID | doaj pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 4430 |
| SubjectTerms | 38/23 631/67/322 692/308/2779/109/1941 692/4028/67/1059/2325 692/4028/67/1347 Adult Aged Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers Biomarkers, Tumor - genetics Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - mortality Breast Neoplasms - pathology Cancer therapies Chemotherapy Diarrhea ErbB-2 protein ESR1 protein Female Genomic analysis Growth factors Humanities and Social Sciences Humans Immune checkpoint inhibitors Immunotherapy Ipilimumab - administration & dosage Ipilimumab - adverse effects Ipilimumab - therapeutic use Metastases Metastasis Microbiomes Middle Aged multidisciplinary Mutation Neoplasm Metastasis Nivolumab - administration & dosage Nivolumab - adverse effects Nivolumab - therapeutic use Patients PD-L1 protein Progression-Free Survival PTEN protein Receptor, ErbB-2 - genetics Receptor, ErbB-2 - metabolism Response rates Science Science (multidisciplinary) Survival Treatment Outcome Tumors |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NaxsxEBUlUOil9LubJkWFHlpakdXHytrckpJgF-JDm0BuQtJK9YK9Nvaa0n-fkXbtxk1DL4U9rXQYNE8zb5D0BqH31cBGnShOKMwgwgVBVGCGcCXAJ5b5YONr5IuxHF6Jr9fF9a1WX_FOWCcP3C3cEbOyEAaIry-coGZgDfUKvkpVTDKfqFFe5reKqRSDeQmli-hfyeRcHa1Eigmxe2tRyrIgdCcTJcH-v7HMu5cl_zgxTYno_Al63DNIfNJZ_hQ98M0z9LDrKfnrOWrHdYo4xuLFdL3C0_lPUs1XHteLelrP0kDd4AnUn8vZOlLNCg_PvjHS-B9JBBzPfGviO6PaYRuvrLfYRWgsj7HBiwlkPTwa4dTtA38Yjy5Or75_fIEuz88uvwxJ31qBOFGKlrjKATcJFWWViCdxQUlheaBlUFYGGqhV3FhOReG55cqoIjgugEpYa0pG-Uu018wb_xphURW5L42NVa1w4FoZpDdmwINK2oAZ-rRZZb3oBDR0OvjmSnc-0eATnXyiaYZOoyO2M6P4dfoBkNA9JPS_IJGhg40bdb8jV5ozCFexhWKZoXfbYdhL8YDENH6-TnMANxE5GXrVeX1riYBUD_QWRtQOHnZM3R1p6knS66YMeJkUeYY-b6Dz267712L_f6zFG_SIRcxHvVl-gPba5dofAo1q7du0Y24ALGAZGw priority: 102 providerName: Directory of Open Access Journals – databaseName: HAS SpringerNature Open Access 2022 dbid: AAJSJ link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3da9swEBelZbCXse-564YGe9jYxKIPK_Le0tGSBJqHtYW-CcmWGkNih8Sh9L_fSbYzsnUPAz_5ZDj0u5PufNLvEPpYDG3gieKEwggici-I8swQrgRgYpnzNtxGvpjJ8bWY3qQ3B4j1d2Hiof1IaRmX6f502LeNiC4dmq-mmcxSAhnPkRpyCc54NBpNL6e7PyuB81wJ0d2QGXD1wMd7u1Ak638owvz7oOQf1dK4CZ0_RU-66BGPWn2foQNXPUeP2n6S9y9QMyvjamMsXi22G7yo70hRbxwuV-WiXEZBWeE55J7r5TaEmQUen_1kpHK3kQAcL11jwh2jMsc2HFdvcB7MYv0dG7yaw46HJxMcO33gT7PJxen15eeX6Or87OrHmHRtFUguMtGQvMghLvEFZYUIVTivpLDc08wrKz311CpuLKciddxyZVTqcy4gjLDWZIzyV-iwqiv3BmFRpAOXGRsyWpEDrNJLZ8yQexV5ARP0pZ9lvWrJM3QsenOlW0w0YKIjJpom6DQAsRsZiK_ji3p9qztD0MzKVBjIg1yaC2qG1lCn4ClUwSRzJkEnPYy688aN5gyWqtA-MUvQh50Y_CgUR0zl6m0cA3YTLCdBr1vUd5oI2OYhtAWJ2rOHPVX3JVU5j1zdlEFMJsUgQV970_mt17_n4vj_hr9Fj1mw7sAqy0_QYbPeuncQLDX2fecdvwAOdA9z priority: 102 providerName: Springer Nature |
| Title | Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS) |
| URI | https://link.springer.com/article/10.1038/s41467-025-59695-1 https://www.ncbi.nlm.nih.gov/pubmed/40360544 https://www.proquest.com/docview/3204058919 https://www.proquest.com/docview/3203919184 https://pubmed.ncbi.nlm.nih.gov/PMC12075640 https://doaj.org/article/2b654a255e5c41a7ba1e81e8d8d262ea |
| Volume | 16 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1ba9swFBZby2AvY_d67YIGe9jYRKOLHXkvIwnJkkDD6AXyZiRbagyJ7SYOY_9-R4qTkt3A2CDpQdZ3JH3Skb6D0Puso51OFCcUShCRWkGkZYpwKQATzYzV7jbyxTQa3YjJLJw1G27r5ljlbkz0A3VWpm6P_JwzMDcXAi_-Wt0RFzXKeVebEBoP0TEFJuJCN3Rmnf0ei1M_l0I0d2XaXJ6vhR8ZXAzXMI7ikNCD-cjL9v-Na_55ZPI3v6mfjoZP0ZOGR-LuFvhn6IEpnqNH28iSP1-gepr7cUdpXC02a7wof5CsXBucV_kiX_qMvMBzWIWulhtHODM8GlwyUphbLwWOl6ZW7rZRnmLtDq7XOHUGsvqCFa7mMPfh8Rj7mB_4w3R80bu5-vgSXQ8H1_0RaQIskFTEoiZplgJDsRllmXD-OCsjobmlsZU6stRSLbnSnIrQcM2lkqFNuQBCobWKGeWv0FFRFuYEYZGFbRMr7da2IgWAIxsZpTrcSq8QGKBPu1ZOqq2MRuLd31wmW0wSwCTxmCQ0QD0HxL6kk8D2CeXqNml6VMJ0FAoFKyITpoKqjlbUSHgymbGIGRWgsx2MSdMv18m9FQXo3T4bepRzk6jClBtfBuzGWU6AXm9R39dEwIQPJBdy5IE9HFT1MKfI5161mzJgZ5FoB-jzznTu6_Xvtnjz_984RY-Zs2anJ8vP0FG92pi3QJNq3fJ9Ad5y-K2FjrvdydUEvr3B9PslpPajfstvQPwCby8WCw |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZGJwQviDuBAUYCCcSs1ZekDtKEKGxq2Vqh0Ul7s-zYXiO1SWlTTftx_DdsN-lUbm-T8hRbkePz-ZxjH5_zAfBad5SvE0URdj0QyyxD3BKJKGdOJooYq3w28mCY9E7Z17P4bAv8bHJh_LXKRicGRa3LzJ-R71Hi4OYp8NKPsx_Is0b56GpDoSFragW9H0qM1YkdR-bywm3hFvv9L07ebwg5PBh97qGaZQBlLGUVynTmzLTVmGjmg1KWJ0xRi1PLVWKxxYpTqShmsaGKcsljm1HmrKpSMiWYus_eANvMn5-0wHb3YPjtZH3I48uvc8bqZJ025XsLFlSTJ5GN0ySNEd4wiIE34G_O7p93Nn8L3AZ7eHgX3KkdWfhphbx7YMsU98HNFbXl5QNQDfOg-KSCs8lyASflBdLlwsB8lk_yaWjICzh22-D5dOk9Xg17BycEFeY81CKHU1NJn-6UZ1D5m_MVzDxC5x-ghLOxM76w34eBdAS-HfYH3dPv7x6C0XXM_SPQKsrCPAGQ6bhtUqn85pplDmGJTYyUHWp5KFEYgffNLIvZqo6HCPF3ysVKJsLJRASZCByBrhfEuqevwR1elPNzUS9pQVQSM-m2ZCbOGJYdJbHh7tFck4QYGYGdRoyiVgwLcQXjCLxaN7sl7eM0sjDlMvRxuPHIicDjldTXI2HO43BetmvhG3jYGOpmS5GPQ9lwTJx7mLB2BHYb6FyN699z8fT_v_ES3OqNBsfiuD88egZuE49sX9yW7oBWNV-a585nq9SLemVAIK55Lf4CiadS9w |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGEIgXxJ3AACOBBIKo9SWJg4QQY6tWxioEm9Q3y07sNVKblDbVtJ_Gv-PYSTqV29ukPMVW5Ph85-bjcw5CL_JEuzpRLCQwI-SZ5aGwVIVMcKCJpsZql418NIoPTvjncTTeQj-7XBh3rbKTiV5Q51Xmzsh7jALcXAu8tGfbaxFf9wYf5j9C10HKRVq7dhoNRA7N-Rm4b8v3wz2g9UtKB_vHnw7CtsNAmPGU12GWZ6CibU5ozl1AyoqYa2ZJaoWOLbFEC6Y0IzwyTDOhRGQzxkGjaq1SShh89gq6mjDQ6sBKyThZH--4wuuC8zZNp89Eb8m9UHLtY6M0TqOQbKhC3zHgb2bun7c1fwvZek04uIVutiYs_thg7jbaMuUddK1panl-F9Wjwos8pfF8ulriaXUW5tXS4GJeTIuZHyhKPAEHeDFbOVs3xwf732hYmlNfhRzPTK1colORYe3uzNc4c9hcvMMKzyegdvFwiH27EfxqNDzaPfn--h46voydv4-2y6o0DxHmedQ3qdLOreYZYCu2sVEqYVb44oQBetPtspw3FTykj7wzIRuaSKCJ9DSRJEC7jhDrma76tn9RLU5ly8yS6jjiCpwxE2WcqEQrYgQ8uchpTI0K0E5HRtmKhKW8AHCAnq-HgZldhEaVplr5OYAbh5wAPWiovl4JB1sD7GsYERt42Fjq5khZTHzBcELBMIx5P0BvO-hcrOvfe_Ho_7_xDF0HDpRfhqPDx-gGdcB2VW3ZDtquFyvzBIy1Wj_1bIGRvGQ2_AVgUFCb |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Nivolumab+plus+low-dose+ipilimumab+in+hypermutated+HER2-negative+metastatic+breast+cancer%3A+a+phase+II+trial+%28NIMBUS%29&rft.jtitle=Nature+communications&rft.au=Barroso-Sousa%2C+Romualdo&rft.au=Zanudo%2C+Jorge+Gomez+Tejeda&rft.au=Li%2C+Tianyu&rft.au=Reddy%2C+Sangeetha+M.&rft.date=2025-05-13&rft.issn=2041-1723&rft.eissn=2041-1723&rft.volume=16&rft.issue=1&rft_id=info:doi/10.1038%2Fs41467-025-59695-1&rft.externalDBID=n%2Fa&rft.externalDocID=10_1038_s41467_025_59695_1 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2041-1723&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2041-1723&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2041-1723&client=summon |